View Document Preview and Link Open Document File Size: 3,34 MB Share Result on Facebook
Company IgG / Hematology Laboratory / Wyeth / / Country United States / / Event FDA Phase / / Facility Performing laboratory / / Holiday between day / / IndustryTerm prevention of invasive disease / injection site / acute otitis media / vaccine treated / relative food consumption / autonomic and central nervous systems / otitis media / injection-site / food / / MedicalCondition especially invasive pneumococcal disease / pneumonia / microscopic subcutaneous inflammation / necrosis / minimal necrosis / bacteremia / mild local inflammatory reactions / invasive disease / pneumococcal disease / injection irritation / acute otitis media / degeneration/necrosis / erythema / Chronic inflammation / inflammatory changes / irritation / otitis media / inflammation / meningitis / microscopic degeneration/necrosis / microscopic inflammation / / MedicalTreatment active immunization / / Person Julienne Vaillancourt / Martin Green / Alum Adsorbed / Claudia Wrzesinski / / Position Chair / Review Committee / Hb / / Product Heart Ileum Injection / SC / sodium chloride / Sorbitol / Prevnar 13 (13vPnC) / isoflurane / ALP04 / VALENT PNEUMOCOCCAL CONJUGATE VACCINE / / ProvinceOrState South Carolina / / Technology CRM / antibodies / / SocialTag 
Toxicology Review of BLA/STN[removed]Pneumococcal 13-Valent Conjugate (Prevnar plus Diphtheria CRM197saccharide conjugates for Types 1, 3, 5, 6A, 7F and 19A) Vaccine, Alum Adsorbed Date: [removed]